Cardiovascular Market has remained a leading therapy area in the global pharmaceutical market
The Cardiovascular Market Outlook to 2015: Competitive landscape, global market analysis, key trends and pipeline analysis
The Cardiovascular Market Outlook to 2015 provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each indication, in order to enable the reader to identify growing brands, key drug classes and leading players through 2015. ( http://www.bharatbook.com/detail.asp?id=134308&rt=The-Cardiovascular-Market-Outlook-to-2015-Competitive-landscape-global-market-analysis-key-trends-and-pipeline-analysis.html )
The cardiovascular market may be segmented into numerous subcategories, including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents. While established treatments are currently available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs still exists. Among the various cardiovascular indications, dyslipidemia had the highest prevalence in 2009, with approximately 333m people affected by the condition.
The global cardiovascular market is quite dynamic and has remained a leading therapy area in the global pharmaceutical market. The seven major markets (7MM) captured a significant market share of the global cardiovascular market and also recorded a moderate Y-o-Y growth in 2009. The US continued to be a dominant market and registered a Y-o-Y increase in 2009, mainly attributed to the performance of key categories such as statins and beta blockers.
In terms of pipeline developments, the thrombosis market has witnessed a lot of activity, with promising new drugs such as Sanofi-Aventis' Multaq (launched in the US in 2009), J&J/Bayer's Xarelto (launched in 2008), Pfizer/BMS's apixaban (under registration), Eli Lilly/Daiichi Sankyo's Effient (approved in 2009) and Boehringer Ingelheim's Pradaxa (launched in 2008). These oral drugs are expected to widen the thrombosis market significantly, while also extending the prescription period. Additionally, these new generation drugs are set to undermine Lovenox's (Sanofi-Aventis) monopoly in the thrombosis market.
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=134308&rt=The-Cardiovascular-Market-Outlook-to-2015-Competitive-landscape-global-market-analysis-key-trends-and-pipeline-analysis.html
Related Reports
Global Cardiovascular Devices Market 2008-2012
http://www.bharatbook.com/detail.asp?id=129839&rt=Global-Cardiovascular-Devices-Market-2008-2012.html
India Cardiovascular Devices Market Outlook to 2016
http://www.bharatbook.com/detail.asp?id=140387&rt=India-Cardiovascular-Devices-Market-Outlook-to-2016.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com
About the Author:
Bharat Book Bureau, the leading market research information aggregator provides reports, company profiles, newsletters, country info. and online databases for the past twenty two years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our reports help global companies to know different market before starting up business / expanding in different countries across the world.